Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects

British Journal of Clinical Pharmacology

Volumn 62, Issue 2, 2006, Pages 210-217

  Smulders, R A ^a   Kuipers, M E ^a   Krauwinkel, W J J ^a  

^a Astellas Pharma Global Development   (Netherlands)

Author keywords

Digoxin; Overactive bladder; Pharmacokinetics; Solifenacin succinate; Warfarin; YM905

Indexed keywords

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; AREA UNDER CURVE; CARDIOTONIC AGENTS; DIGOXIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; WARFARIN;

EID: 33748263046     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02638.x     Document Type: Article

References (28)

1. McGhan WF. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am J Manag Care 2001; 7 (2 Suppl.): S62-75.
2. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urol 2002; 60 (Suppl. 5A): 7-12.
3. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Kerrebroeck P, Victor A, Wein A. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urology 2003; 61: 37-49.
4. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6.
5. Versi E. Screening initiative confirms widespread prevalence of overactive bladder in American adults. Int Urogynecol J 2001; 12: S13.
6. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55 (Suppl. 5A): 33-46.
7. Chapple CR, Arano P, Bosch JLHR, De Ridder D, Kramer AEJL, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004; 93: 71-7.
8. Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M, Yamada T, Honda K. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naun-Schmied Arch Pharmacol 2002; 366: 97-103.
9. Hatanaka T, Ukai M, Ohtake A, Kobayashi S, Ikeda K, Sato S, Miyata K, Sasamata M. In vitro tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats and monkeys. Presented at the International Continence Society 33rd Annual Meeting. Florence, Italy. Poster no. 312. 5-9 October 2003.
10. Ohtake A, Hatanaka T, Ikeda K, Sato S, Miyata K, Sasamata M. In vivo bladder selective profile of solifenacin succinate (YM905) over salivary gland in mice and rats. Presented at the International Continence Society 33rd Annual Meeting. Florence, Italy. Poster no. 297. 5-9 October 2003.
11. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-10.
12. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002; 72: 474-89.
13. Wienkers LC. Problems associated with in vitro assessment of drug inhibition of CYP3A4 and other P-450 enzymes and its impact on drug discovery. J Pharmacol Toxicol Meth 2001; 45: 79-84.
14. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
15. Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve Clin J Med 2003; 70: 361-71.
16. De Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992; 189: 551-7.
17. Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001; 21: 778-96.
18. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159-68.
19. Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, Rost KL. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 1999; 66: 391-400.
20. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000; 68: 6-12.
21. Michel MC, Minematsu T, Hashimoto T, den Hoven WV, Swart PJ. In vitro studies on the potential of solifenacin for drug-drug-interactions: plasma protein binding and MDR1 transport. Proceedings of the British Pharmacological Society Clinical Pharmacology Section 14-16 December 2004. Br J Clin Pharmacol 2005; 59: 647.
22. Yates RA, Wong J, Seiberling M, Merz M, Marz W, Nauck M. The effect of anastrozole on the single dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol 2001; 51: 429-35.
23. Priskorn M, Sidhu JS, Larsen F, Davis JD, Khan AZ, Rolan PE. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997; 44: 199-202.
24. Pitsiu M, Parker EM, Aarons L, Holt B, Rowland M. A comparison of the relative sensitivities of factor VII and prothrombin time measurements in detecting drug interactions with warfarin. Eur J Clin Pharmacol 1992; 42: 645-9.
25. Toon S, Hopkins KJ, Garstang FM, Rowland M. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol 1987; 32: 165-72.
26. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1992; 30 (Suppl. 1): S37-S43.
27. Smulders RA, Krauwinkel WJ, Swart PJ, Huang M. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol 2004; 44: 1023-33.
28. Krauwinkel WJJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink MEJ. Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 2005; 43: 227-38.